Population pharmacokinetics of posaconazole in allogeneic haematopoietic stem cell transplant patients

ConclusionsIncreased doses of posaconazole should be considered for both prophylaxis and treatment of IFD to increase the proportion of alloHCT patients achieving therapeutic exposures, particularly the oral formulation in patients with mucositis and/or diarrhoea. Posaconazole therapeutic drug monitoring should be considered for all formulations in this setting.
Source: Journal of Antimicrobial Chemotherapy - Category: Microbiology Source Type: research